News and milestones.

1. 2026

   Care Onco begins regulatory work with CDSCO

   With the TEPScan kit formulated and 150 breast cancer validations complete, Care Onco has started regulatory work with India’s Central Drugs Standard Control Organisation (CDSCO), ahead of a Research Use Only launch for NSCLC and head & neck cancer.

2. January 2026

   IIIT-Delhi’s AI blood test research featured in the national press

   The Tribune reported on the IIIT-Delhi research led by Prof. Debarka Sengupta that underpins TEPScan: an AI blood test that reads cancer-induced changes in platelets, including in Stage I and II disease.

   Source: The Tribune: IIIT-Delhi researchers develop AI tools to detect early-stage cancer with a simple blood test ›

3. 2025

   Prof. Debarka Sengupta receives the Rashtriya Vigyan Puraskar

   Prof. Debarka Sengupta, inventor of TEPScan, received the Rashtriya Vigyan Puraskar (Vigyan Yuva–Shanti Swarup Bhatnagar) in Biological Sciences, one of India’s highest honours for science.

4. 27 October 2020

   11-platelet-gene signature published in BMC Genomics

   The peer-reviewed paper behind TEPScan showed that a signature of just 11 platelet genes enables accurate blood-based diagnosis of non-small cell lung cancer, matching the performance of a much larger gene panel.

   Source: Goswami et al., BMC Genomics 21:744 (2020) ›

Subscribe with RSS: careonco.ai/feed.xml